Our keywords
In this editorial, Alberto Costa, who has taken over from Kathy Redmond, pays tribute to her achievements, reaffirms the magazines founding principles, and flags up changes to style and content that will expand the reach [more]
2015
Kathy Redmond: We need to talk
As founding editor of Cancer World, Kathy Redmond set out to open up debate on the future of cancer care in Europe. She started a conversation that a full range of professionals and patient advocates [more]
Getting serious about biosimilars
As patents on the first generation of monoclonal antibodies begin to expire, the cancer community will need to get to grips with the unique issues involved in ensuring the safety and efficacy of copies of [more]
Asking the value for money questions
Delivering the best possible quality of cancer care to every patient requires getting value for money from scarce resources. BBC journalist Matthew Hill earned himself a Best Cancer Reporter Award for taking a critical look [more]
Living well with advanced breast cancer
Sustaining a good quality of life becomes harder as cancers progress. Advocates are saying their needs have gone unmet for too long, and are working with professionals to define what they need and how best [more]
Managing common toxicities with new tyrosine kinase inhibitors
TKIs are involved in treating an increasing number of cancer indications. Doctors need to be aware of the range of potentially serious side effects associated with these drugs, and know how to mitigate them, to [more]
Dangerous Healers
Its not uncommon for people diagnosed with cancer to explore how alternative practitioners might help. Some can, or at least do no harm. But the chances of running into a charlatan whose advice could be [more]
Goodbye or arrivederci?
Our new vocabulary gene, genome, molecular, targeted, personalised no longer inspires the confidence it once did, and as the cancer community prepares to gather at the 18th ECCO – 40th ESMO European Cancer [more]
Denis Lacombe quietly orchestrating the clinical research revolution
The scientific complexity and economic cost of developing new cancer therapies demand a level of collaboration and sharing that takes both industry and academia well beyond their comfort zones. EORTC head Denis Lacombe believes he [more]
What can we learn from liquid biopsies?
Early detection, disease prognosis, a guide to treatment, a key to unlock the secrets of how cancers evolve. Researchers have high hopes for what they can learn from the biological detritus shed by primary tumours [more]
Asking the dumb questions
It took ten years of immersion in the world of cancer research to produce the book that won Clifton Leaf a Best Cancer Reporter Lifetime Achievement award. But it started from a simple question: how [more]
Does lack of physical exercise jeopardise a patient’s chances of survival?
Exercise reduces the risks of getting some cancers but what about after diagnosis? What should we be advising our patients? Be physically active in everyday life. Limit the time you spend sitting.” So says [more]